RYTM

Analyst Note: Rhythm Pharmaceuticals, Inc. (RYTM)

Date: June 20, 2026 Subject: Structural Setup & Business Thesis Review

1. Structural Readiness

Current State: Forming Entry Levels:

Current Price: $96.79. Extension: None (Price is within the forming range, not extended above the breakout level). Volatility Context: Current ATR is 4.7% (High). This indicates elevated volatility, which is within the historical "sweet spot" (4–6%) for structural quality, suggesting the setup has sufficient momentum to potentially break out, but also implies wider stop distances for risk management.

• Conservative Entry: Not available (requires confirmed breakout).
• Aggressive Entry: $91.50 (Pre-breakout / forming entry).
• Breakout Level: $122.20 (Resistance level that must be cleared to confirm the setup).

2. Thesis Layer

Primary Secular Theme: Biotech & GLP-1 → Rare & Orphan. Exposure: Direct. Thesis Weighting: Rhythm Pharmaceuticals is a primary beneficiary of the secular shift toward targeted therapies for rare genetic and acquired metabolic disorders. The company operates at the intersection of the "Rare & Orphan" theme and the broader "Biotech & GLP-1" narrative, specifically through its melanocortin-4 receptor (MC4R) pathway agonists. Context: The company is not merely a passive participant but a direct innovator in a niche with high unmet medical need. The approval of IMCIVREE for acquired hypothalamic obesity (HO) in March 2026 validates the company's ability to expand its addressable market beyond its initial syndromic obesity indications. This dual exposure (syndromic + acquired) strengthens the conviction in the "Rare & Orphan" thesis, as it demonstrates a platform capability to treat both genetic and acquired forms of the same pathway.

3. Business Overview

Company Role: Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, specifically those involving the MC4R pathway. Business Model: The company generates revenue through the direct sale of its approved product, IMCIVREE (setmelanotide), to specialty pharmacies and healthcare providers. Key Business Metrics & Evidence (as of June 20, 2026):

• Product Portfolio: IMCIVREE is the sole commercial product. It is approved for syndromic/monogenic obesity (BBS, POMC, PCSK1, LEPR) and, as of March 19, 2026, for acquired hypothalamic obesity (HO) in the U.S. and Europe.
• Revenue Performance: For the first quarter of 2026, the company reported revenues of $60.1 million, representing a 5% sequential increase from Q4 2025. This growth is attributed to sales of IMCIVREE for Bardet-Biedl syndrome (BBS) and an increase in the number of patients on reimbursed therapy globally.
• Market Access: In the U.S., the company sells its product to a single specialty pharmacy. As of the Q1 2026 earnings call, the company had received more than 150 start forms in the six weeks following the HO approval, with approximately 40 of these being for clinical trial patients.
• Pipeline & R&D:
• Bivamelagon: CMC work and bioequivalence studies for a new formulation are underway. Management expects to initiate a Phase III trial for bivamelagon in acquired HO by the end of 2026.
• Setmelanotide (PWS): Positive interim results from an exploratory Phase 2 trial in Prader-Willi Syndrome (PWS) were announced in December 2025, showing BMI and hyperphagia reductions.
• RM-718: An ongoing Phase 1/2 trial in acquired HO is evaluating this new candidate.
• EMANATE Trial: The Phase 3 EMANATE trial, evaluating setmelanotide in genetically caused MC4R pathway diseases, was expected to report topline data in March 2026.
• Financial Position: As of March 31, 2026, the company held approximately $341 million in cash, cash equivalents, and short-term investments. Management stated at the May 5, 2026 earnings call that these funds are sufficient to fund planned operations for at least 24 months.

4. Archetype & Conviction

Archetype: Growth Leader. Rationale: Rhythm fits the "Growth Leader" archetype due to its transition from a pure R&D biotech to a commercial entity with a growing revenue base ($60M Q1 2026) and a clear path to market expansion via the newly approved HO indication. The company is executing on a multi-stage pipeline (bivamelagon, RM-718) that targets the same pathway, suggesting potential for future product launches. Conviction Stack:

• Thesis Strength: High. The "Rare & Orphan" theme is robust, and Rhythm is a direct beneficiary with a validated mechanism of action.
• Evidence Quality: Strong. The evidence base includes specific financial data ($60.1M revenue), clear regulatory milestones (FDA approval March 2026), and defined management guidance for upcoming trials.
• Rerating Potential: Significant. The expansion into acquired HO (prevalence ~10,000 in US/EU) opens a larger market than the initial syndromic indications. If the Phase III bivamelagon trial initiates as planned and data remains positive, the company could see a re-rating based on the expansion of its total addressable market (TAM).
• Valuation Context: While specific valuation multiples are not provided in the evidence, the company's cash runway (24 months) and revenue growth provide a stable financial spine for a growth story, reducing near-term dilution risk compared to pre-revenue peers.

5. Invalidation, Strengthening, and Gaps

What Would Invalidate the Case:

• Business Invalidation: Failure to initiate the Phase III bivamelagon trial by the end of 2026 as guided, or negative data from the ongoing Phase 1/2 RM-718 trial.
• Financial Invalidation: A significant burn rate acceleration that threatens the 24-month cash runway before the next catalyst.

What Would Strengthen the Case:

• Structural Strengthening: A confirmed breakout above $122.20 with volume, confirming the "Forming" coil into a "Confirmed" coil.
• Business Strengthening: Positive topline data from the EMANATE trial (if not yet fully disclosed) or the Japanese cohort data mentioned in the February filing.
• Commercial Strengthening: Acceleration in the number of start forms or patient onboarding beyond the 150 reported in May 2026.

Gaps in Evidence:

• Specific Revenue Guidance: While Q1 2026 revenue is known, specific full-year 2026 revenue guidance or margin targets were not explicitly detailed in the provided evidence snippets.
• Pricing/Reimbursement Details: The evidence mentions "reimbursed therapy" but does not provide specific pricing data or reimbursement rates for the new HO indication, which are critical for forecasting the $60M run-rate.
• Competitive Landscape: No specific evidence regarding competitive pressures or pipeline developments from other companies in the acquired HO space is provided.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: FDA approval for acquired HO in March 2026 expanding TAM; Q1 2026 revenue of $60.1M with sequential growth; strong cash position ($341M) funding 24 months of operations. Expected path: Management expects to initiate Phase III bivamelagon trials by end of 2026; commercial ramp for HO is expected to drive sequential revenue growth; price likely consolidates in the $90-$120 range until a catalyst (trial initiation or data readout) triggers a breakout. Expected horizon: 6 to 12 months for the next major catalyst (Phase III initiation or data readout). Failure mode to watch: A daily close below $84.90, which would invalidate the forming coil structure and suggest a loss of market confidence in the near-term catalysts.